| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/15/2011 | US20110223174 Nontypeable Haemophilus Influenzae Virulence Factors |
| 09/15/2011 | US20110223173 Botulinum Neurotoxin A Receptor and the Use Thereof |
| 09/15/2011 | US20110223172 Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof |
| 09/15/2011 | US20110223171 Methods and Compositions for the Diagnosis and Treatment of Cyclin A-1 Associated Conditions |
| 09/15/2011 | US20110223170 Klk-13 antibody inhibitor for treating dry eye |
| 09/15/2011 | US20110223169 Il-17 antibody inhibitor for treating dry eye |
| 09/15/2011 | US20110223168 Ligand that has binding specificity for il-4 and/or il-13 |
| 09/15/2011 | US20110223167 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| 09/15/2011 | US20110223166 Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death |
| 09/15/2011 | US20110223165 Humanized C-Kit Antibody |
| 09/15/2011 | US20110223164 Binding domain-immunoglobulin fusion proteins |
| 09/15/2011 | US20110223163 Monoclonal antibodies that react with the capsule of bacillus anthracis |
| 09/15/2011 | US20110223162 Targeting pax2 for the treatment of breast cancer |
| 09/15/2011 | US20110223161 Targeting pax2 for the treatment of breast cancer |
| 09/15/2011 | US20110223160 Compositions and methods relating to glucagon receptor antibodies |
| 09/15/2011 | US20110223159 Tumor therapy with an anti-vegf antibody |
| 09/15/2011 | US20110223158 Association of levels of hdl-cholesterol apolipoprotein ciii with the risk of coronary heart disease and cardiovascular events |
| 09/15/2011 | US20110223157 Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| 09/15/2011 | US20110223156 Reversible gel protein formulation |
| 09/15/2011 | US20110223155 Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| 09/15/2011 | US20110223154 Compositions including triciribine and methods of use thereof |
| 09/15/2011 | US20110223153 Modified silk films containing glycerol |
| 09/15/2011 | US20110223152 Use of inhibitors of leukotriene b4 receptor blt2 for treating human cancers |
| 09/15/2011 | US20110223133 Therapeutic agent for hematopoietic tumors |
| 09/15/2011 | US20110223130 USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE |
| 09/15/2011 | US20110223107 Antibodies that specifically block the biological activity of a tumor antigen |
| 09/15/2011 | CA2849668A1 Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
| 09/15/2011 | CA2811221A1 Humanized and chimeric anti-properdin antibodies |
| 09/15/2011 | CA2792691A1 Vaccine |
| 09/15/2011 | CA2792689A1 Immunogenic composition |
| 09/15/2011 | CA2792687A1 Immunogenic composition |
| 09/15/2011 | CA2792683A1 Vaccine composition |
| 09/15/2011 | CA2792679A1 A novel mucosal vaccination approach for herpes simplex virus type-2 |
| 09/15/2011 | CA2792618A1 Cd37-binding molecules and immunoconjugates thereof |
| 09/15/2011 | CA2792369A1 Vaccines for pandemic influenza |
| 09/15/2011 | CA2792327A1 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| 09/15/2011 | CA2792118A1 Bluetongue virus recombinant vaccines and uses thereof |
| 09/15/2011 | CA2792117A1 Foot and mouth disease virus recombinant vaccines and uses thereof |
| 09/15/2011 | CA2791946A1 Treatment of streptococcal infections |
| 09/15/2011 | CA2791926A1 Conjugation process |
| 09/15/2011 | CA2791915A1 Immunogenic composition comprising s. pneumoniae polysaccharides conjugated to carrier proteins |
| 09/15/2011 | CA2791863A1 Monoclonal antibodies against c-met |
| 09/15/2011 | CA2791396A1 Method for protecting against disease caused by secondary pathogens |
| 09/15/2011 | CA2789238A1 Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening |
| 09/14/2011 | EP2365082A1 BVDV virus-like particles |
| 09/14/2011 | EP2365081A2 13 Transmembrane protein expressed in prostate cancer |
| 09/14/2011 | EP2365071A1 Transformed soybean plant which stores vaccine, and use thereof |
| 09/14/2011 | EP2365006A2 Novel anti-IGF-IR antibodies and uses thereof |
| 09/14/2011 | EP2365005A2 Novel anti-IGF-IR antibodies and uses thereof |
| 09/14/2011 | EP2365004A2 Membrane associated tumor endothelium markers |
| 09/14/2011 | EP2365003A1 CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| 09/14/2011 | EP2365001A2 Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| 09/14/2011 | EP2364998A1 Antibodies against HMGB1 and fragments thereof |
| 09/14/2011 | EP2364997A2 Polypeptide variants with altered effector function |
| 09/14/2011 | EP2364996A1 Optimized FC variants and methods for their generation |
| 09/14/2011 | EP2364994A1 Purfied primate CTLA-8 antigens and related reagents |
| 09/14/2011 | EP2364732A1 Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| 09/14/2011 | EP2364731A2 Methods of administering anti-TNFalpha antibodies |
| 09/14/2011 | EP2364730A2 Immunoglobulin preparations having increased stability |
| 09/14/2011 | EP2364729A2 IL-17 antagonistic antibodies |
| 09/14/2011 | EP2364728A1 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
| 09/14/2011 | EP2364727A2 Molecular antigen array |
| 09/14/2011 | EP2364726A2 Vaccine against neisseria infection |
| 09/14/2011 | EP2364725A2 Immunization method against neisseria meningitidis serogroups a and c |
| 09/14/2011 | EP2364724A1 Vaccine compositions comprising a saponin adjuvant |
| 09/14/2011 | EP2364723A1 Vaccine compositions comprising a saponin adjuvant |
| 09/14/2011 | EP2364722A1 Vaccine compositions comprising a saponin adjuvant |
| 09/14/2011 | EP2364721A1 Vaccine compositions comprising a saponin adjuvant |
| 09/14/2011 | EP2364720A1 Vaccine compositions comprising a saponin adjuvant |
| 09/14/2011 | EP2364719A1 Prevention and treatment of amyloidogenic diseases |
| 09/14/2011 | EP2364699A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 09/14/2011 | EP2364362A1 Gene vector for inducing transgene-specific immune tolerance |
| 09/14/2011 | EP2364361A1 Use of bacteria for the sensing and killing of cancer cells |
| 09/14/2011 | EP2364327A1 Binding members against il-1r1 |
| 09/14/2011 | EP2364167A1 Method for production of ph stable enveloped viruses |
| 09/14/2011 | EP2364156A2 Modified protozoan expressing at least two variable surface proteins (vsp), a vaccine comprising it and procedures, uses, and methods thereof |
| 09/14/2011 | EP2364152A2 Methods for preparation and use of marrow infiltrating lymphocytes (mils) |
| 09/14/2011 | EP2301580A9 Container holding anti-VEGF antibodies |
| 09/14/2011 | EP2032160B9 Vaccine |
| 09/14/2011 | EP1844815B1 Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| 09/14/2011 | EP1799253B1 Multivalent canine vaccines against leptospira bratislava and other pathogens |
| 09/14/2011 | EP1761635B1 Non-integrative and non-replicative lentivirus, preparation and uses thereof |
| 09/14/2011 | EP1563301B1 Vaccine for the prevention of malaria |
| 09/14/2011 | EP1469869B1 Peptide useful in immunomodulation |
| 09/14/2011 | EP1441766B1 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| 09/14/2011 | EP1377314B1 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| 09/14/2011 | EP1237582B1 Methods for introducing genes into mammalian subjects |
| 09/14/2011 | EP1027440B2 Inhibitor protein of the wnt signal pathway |
| 09/14/2011 | CN1933851B Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| 09/14/2011 | CN1845988B Method for immunotherapy of tumors |
| 09/14/2011 | CN1561345B Antibodies to VLA-1 |
| 09/14/2011 | CN102186977A Inhbb epitope peptides and vaccines containing the same |
| 09/14/2011 | CN102186882A Treatment of thrombocytopenia |
| 09/14/2011 | CN102186502A Immunological composition |
| 09/14/2011 | CN102186501A Pharmaceutical product for up-dosing of allergy vaccine |
| 09/14/2011 | CN102186500A Mycobacterium tuberculosis vaccine |
| 09/14/2011 | CN102186499A Dock-and-lock (DNL) vaccines for cancer therapy |
| 09/14/2011 | CN102186498A Vaccine for treatment/prevention of scuticociliatosis in fish |
| 09/14/2011 | CN102186497A Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
| 09/14/2011 | CN102186495A Methods of enhancing opsonophagocytosis in response to a pathogen |